Bio Impact Capital LLC Design Therapeutics, Inc. Transaction History
Bio Impact Capital LLC
- $669 Million
- Q4 2024
A detailed history of Bio Impact Capital LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 559,547 shares of DSGN stock, worth $2.31 Million. This represents 0.52% of its overall portfolio holdings.
Number of Shares
559,547Holding current value
$2.31 Million% of portfolio
0.52%Shares
1 transactions
Others Institutions Holding DSGN
# of Institutions
97Shares Held
32.1MCall Options Held
4.6KPut Options Held
2.6K-
Sr One Capital Management, LP6.53MShares$27 Million14.99% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$17.4 Million3.42% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$9.52 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$8.07 Million0.72% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.86MShares$7.67 Million0.03% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $230M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...